National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

Met tyrosine kinase inhibitor BMS-777607
An inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibitor BMS-777607 binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway; this agent may induce cell death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:BMS-777607



Previous:Merrem I.V., mesna, Mesnex, mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine, MET receptor tyrosine kinase inhibitor SGX523
Next:MET tyrosine kinase inhibitor PF-02341066, MET tyrosine kinase inhibitor PF-04217903, Metastat, Metastron, metformin hydrochloride

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov